Literature DB >> 27623761

Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats.

Cameron G McCarthy1, Camilla F Wenceslau2, Styliani Goulopoulou3, Babak Baban4, Takayuki Matsumoto5, R Clinton Webb2.   

Abstract

BACKGROUND: Innate immune system responses to damage-associated molecular patterns (DAMPs) are involved in hypertension. However, the mechanisms of this contribution are not well understood. Circulating mitochondrial DNA is a DAMP that activates Toll-like receptor (TLR) 9 and is elevated in spontaneously hypertensive rats (SHR). Therefore, we hypothesized that lysosomotropic agent chloroquine (CQ) would impair TLR9 signaling, as well as prevent the development of hypertension and immune cell recruitment to the vasculature, in SHR.
METHODS: Initially, adult SHR and Wistar-Kyoto (WKY) rats (12 weeks old), as well as a group of young SHR (5 weeks old), were treated with CQ (40mg/kg/day) or vehicle (saline) via intraperitoneal injections for 21 days and then TLR9-myeloid differentiation primary response protein (MyD88) signaling proteins were assessed in mesenteric resistance arteries (MRA) via western blot. Subsequently, young SHR and WKY were treated from 5-8 weeks of age and then were allowed to mature without further treatment. Blood pressure was measured pretreatment, posttreatment, and after maturation, and immune cell recruitment to the vasculature was measured via flow cytometry after maturation.
RESULTS: In MRA from adult SHR, CQ increased the expression of MyD88-dependent proteins, whereas young SHR MRA exhibited a decrease. This inhibition was subsequently associated with suppression of blood pressure, as well as decreased counts of circulating T cells and vascular infiltrating leukocytes in SHR, when CQ was administered during the prehypertensive phase.
CONCLUSIONS: These data bring into question the participation of TLRs during the maintenance phase of hypertension and promote the exploration of innate immune system therapy during the critical developmental phase. © American Journal of Hypertension, Ltd 2016. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Toll-like receptors.; blood pressure; hypertension; immune system

Mesh:

Substances:

Year:  2016        PMID: 27623761      PMCID: PMC5225945          DOI: 10.1093/ajh/hpw113

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  40 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

Review 2.  Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.

Authors:  A Wozniacka; A Carter; D P McCauliffe
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 3.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

4.  Physiologic control of IDO competence in splenic dendritic cells.

Authors:  Babak Baban; Phillip R Chandler; Burles A Johnson; Lei Huang; Minghui Li; Marlon L Sharpe; Loise M Francisco; Arlene H Sharpe; Bruce R Blazar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

5.  Passive transfer of autoimmune induced hypertension in the rat by lymph node cells.

Authors:  T Okuda; A Grollman
Journal:  Tex Rep Biol Med       Date:  1967

6.  Chloroquine Inhibits Ca(2+) Signaling in Murine CD4(+) Thymocytes.

Authors:  Jin-Chao Xu; Yong-Bo Peng; Ming-Yu Wei; Yi-Fan Wu; Donglin Guo; Gangjian Qin; Guangju Ji; Jinhua Shen; Qing-Hua Liu
Journal:  Cell Physiol Biochem       Date:  2015-04-27

7.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

8.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

9.  Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation.

Authors:  Lu Long; Xudong Yang; Mark Southwood; Junyu Lu; Stefan J Marciniak; Benjamin J Dunmore; Nicholas W Morrell
Journal:  Circ Res       Date:  2013-02-27       Impact factor: 17.367

10.  CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway.

Authors:  H C DeGrendele; P Estess; L J Picker; M H Siegelman
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  13 in total

1.  Toll-Like Receptors, Hypertension, and an Antimalarial Drug.

Authors:  Madhu V Singh
Journal:  Am J Hypertens       Date:  2016-10-04       Impact factor: 2.689

Review 2.  Toll-Like Receptors Contribute to Sex Differences in Blood Pressure Regulation.

Authors:  Vanessa Dela Justina; Fernanda R Giachini; Jennifer C Sullivan; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2020-09       Impact factor: 3.105

3.  Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.

Authors:  Madhu V Singh; Michael Z Cicha; Sarah Nunez; David K Meyerholz; Mark W Chapleau; François M Abboud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-22       Impact factor: 4.733

Review 4.  Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress.

Authors:  Jean C Bikomeye; Janée D Terwoord; Janine H Santos; Andreas M Beyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-05       Impact factor: 5.125

Review 5.  Circulating Cell-Free Mitochondrial DNA in Pregnancy.

Authors:  Jessica L Bradshaw; Spencer C Cushen; Nicole R Phillips; Styliani Goulopoulou
Journal:  Physiology (Bethesda)       Date:  2022-01-10

Review 6.  Paying the Toll for Inflammation.

Authors:  Cameron G McCarthy; Styliani Goulopoulou; R Clinton Webb
Journal:  Hypertension       Date:  2019-03       Impact factor: 10.190

7.  Necrosis Contributes to the Development of Hypertension in Male, but Not Female, Spontaneously Hypertensive Rats.

Authors:  Mahmoud Abdelbary; Olga Rafikova; Ellen E Gillis; Jacqueline B Musall; Babak Baban; Paul M O'Connor; Michael W Brands; Jennifer C Sullivan
Journal:  Hypertension       Date:  2019-10-28       Impact factor: 10.190

Review 8.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

Review 9.  MyD88: At the heart of inflammatory signaling and cardiovascular disease.

Authors:  Abraham L Bayer; Pilar Alcaide
Journal:  J Mol Cell Cardiol       Date:  2021-08-08       Impact factor: 5.000

Review 10.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.